IFRX Stock Summary and Trading Ideas (Inflarx N.V. | NASDAQ:IFRX)

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Inflarx N.V. trades on the NASDAQ stock market under the symbol IFRX.

As of January 15, 2026, IFRX stock price declined to $1.01 with 415,126 million shares trading.

IFRX has a beta of 1.08, meaning it tends to be more sensitive to market movements. IFRX has a correlation of 0.02 to the broad based SPY ETF.

IFRX has a market cap of $68.42 million. This is considered a Micro Cap stock.

Last quarter Inflarx N.V. reported $27,862 in Revenue and -$.21 earnings per share. This fell short of revenue expectation by $-202,138 and missed earnings estimates by -$.02.

In the last 3 years, IFRX traded as high as $7.25 and as low as $.71.

IFRX has underperformed the market in the last year with a price return of -56.8% while the SPY ETF gained +20.1%. IFRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -21.1% and 0.0%, respectively, while the SPY returned +4.8% and +1.5%, respectively.

IFRX support price is $1.02 and resistance is $1.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IFRX shares will trade within this expected range on the day.